NASDAQ:BIIB

Biogen Stock Forecast, Price & News

$295.82
-2.67 (-0.89 %)
(As of 09/21/2021 03:59 PM ET)
Add
Compare
Today's Range
$292.73
$304.18
50-Day Range
$295.95
$352.06
52-Week Range
$223.25
$468.55
Volume53,758 shs
Average Volume1.45 million shs
Market Capitalization$44.09 billion
P/E Ratio23.74
Dividend YieldN/A
Beta0.41
30 days | 90 days | 365 days | Advanced Chart
Receive BIIB News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.


Biogen logo

About Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

2.55 out of 5 stars

Medical Sector

81st out of 1,352 stocks

Biological Products, Except Diagnostic Industry

8th out of 193 stocks

Analyst Opinion: 4.3Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Biogen (NASDAQ:BIIB) Frequently Asked Questions

Is Biogen a buy right now?

29 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 13 hold ratings and 16 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Biogen stock.
View analyst ratings for Biogen
or view top-rated stocks.

What stocks does MarketBeat like better than Biogen?

Wall Street analysts have given Biogen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Biogen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Biogen?

Biogen saw a increase in short interest during the month of August. As of August 13th, there was short interest totaling 2,180,000 shares, an increase of 21.8% from the July 29th total of 1,790,000 shares. Based on an average trading volume of 1,970,000 shares, the days-to-cover ratio is currently 1.1 days. Currently, 1.5% of the shares of the stock are sold short.
View Biogen's Short Interest
.

When is Biogen's next earnings date?

Biogen is scheduled to release its next quarterly earnings announcement on Wednesday, October 20th 2021.
View our earnings forecast for Biogen
.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) released its quarterly earnings results on Wednesday, July, 21st. The biotechnology company reported $5.68 earnings per share for the quarter, beating the consensus estimate of $4.55 by $1.13. The biotechnology company earned $2.78 billion during the quarter, compared to analysts' expectations of $2.61 billion. Biogen had a trailing twelve-month return on equity of 34.74% and a net margin of 16.40%. The company's quarterly revenue was down 24.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $10.26 earnings per share.
View Biogen's earnings history
.

How has Biogen's stock price been impacted by Coronavirus?

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BIIB shares have increased by 0.7% and is now trading at $296.38.
View which stocks have been most impacted by COVID-19
.

How will Biogen's stock buyback program work?

Biogen announced that its board has initiated a share buyback program on Monday, December 23rd 2019, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to reacquire shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company's leadership believes its shares are undervalued.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share (EPS) guidance of $17.500-$19.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $18.590. The company issued revenue guidance of $10.65 billion-$10.85 billion, compared to the consensus revenue estimate of $10.63 billion.

What price target have analysts set for BIIB?

29 equities research analysts have issued twelve-month price objectives for Biogen's shares. Their forecasts range from $245.00 to $500.00. On average, they expect Biogen's share price to reach $393.36 in the next year. This suggests a possible upside of 32.7% from the stock's current price.
View analysts' price targets for Biogen
or view top-rated stocks among Wall Street analysts.

Who are Biogen's key executives?

Biogen's management team includes the following people:
  • Michel Vounatsos, Chief Executive Officer & Director
  • Alphonse Galdes, EVP-Pharmaceutical Operations & Technology
  • Michael R. McDonnell, Chief Financial Officer & Executive Vice President
  • Alfred W. Sandrock, Executive Vice President-Research & Development (LinkedIn Profile)
  • Mark Hernon, Chief Information Officer & Senior Vice President

What is Michel Vounatsos' approval rating as Biogen's CEO?

186 employees have rated Biogen CEO Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among Biogen's employees.

Who are some of Biogen's key competitors?

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), The Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and The Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (11.04%), BlackRock Inc. (8.86%), Vanguard Group Inc. (7.89%), State Street Corp (4.48%), Jefferies Group LLC (0.00%) and Clearbridge Investments LLC (2.39%). Company insiders that own Biogen stock include Alfred Sandrock, Brian S Posner, Michel Vounatsos and Stephen A Sherwin.
View institutional ownership trends for Biogen
.

Which institutional investors are selling Biogen stock?

BIIB stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, FMR LLC, LSV Asset Management, AQR Capital Management LLC, Bank of New York Mellon Corp, and Clearbridge Investments LLC. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, and Brian S Posner.
View insider buying and selling activity for Biogen
or view top insider-selling stocks.

Which institutional investors are buying Biogen stock?

BIIB stock was acquired by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Amundi, Marshall Wace LLP, Squarepoint Ops LLC, American Century Companies Inc., Westfield Capital Management Co. LP, Legal & General Group Plc, and IMC Chicago LLC.
View insider buying and selling activity for Biogen
or or view top insider-buying stocks.

How do I buy shares of Biogen?

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $296.38.

How much money does Biogen make?

Biogen has a market capitalization of $44.17 billion and generates $13.44 billion in revenue each year. The biotechnology company earns $4.00 billion in net income (profit) each year or $33.70 on an earnings per share basis.

How many employees does Biogen have?

Biogen employs 9,100 workers across the globe.

Does Biogen have any subsidiaries?

The following companies are subsidiares of Biogen: AliveGen, Biogen (Argentina) SRL, Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (Denmark) Manufacturing ApS, Biogen (Denmark) New Manufacturing ApS, Biogen (RTP) Realty LLC, Biogen (Singapore) Pte Ltd, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd., Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Colombia S.A.S., Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding APS, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Hong Kong Limited, Biogen Idec Ltd., Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia SRL, Biogen Japan Ltd., Biogen Korea, Biogen Luxembourg Holding SARL, Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen Mexico Servicios S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o, Biogen Poland Sp. z.o.o, Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Ltd., Eidetica Biopharma GmbH, Fumapharm, Karyopharm Therapeutics, Nightstar Europa Limited, Nightstar Inc., Nightstar Limited, Nightstar Therapeutics, Nightstar Therapeutics Limited, Old Convergence Pharmaceuticals Ltd., Panion Ltd., Remedy Pharmaceuticals, Silver Acquisition Co. Ltd., Stromedix, Stromedix Inc., Syntonix Pharmaceuticals, Tungsten Bidco Limited, and Tysabri.

When was Biogen founded?

Biogen was founded in 1978.

What is Biogen's official website?

The official website for Biogen is www.biogen.com.

Where are Biogen's headquarters?

Biogen is headquartered at 225 BINNEY STREET, CAMBRIDGE MA, 02142.

How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at (617) 679-2000 or via email at [email protected].


This page was last updated on 9/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.